All Posts Tagged With: "AZN"
(QGEN) Qiagen Expands with New Deals
In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement,...
13Jan2012 | vitalstocks | 0 comments | Continued(NVS) Novartis’ Cancer Drug Afinitor Shows Promise for Breast Cancer
Novartis’ (NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an indication for which management estimates sales potential in excess of $1 billion....
12Dec2011 | vitalstocks | 0 comments | Continued(MITI) Micromet Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results. Micromet’s third quarter 2011 loss per share came in at 21 cents (after adjusting for the change in fair value of warrants),...
9Dec2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca Drug Cleared by the European Commission
AstraZeneca (AZN) and its partner Bristol-Myers Squibb (BMY) announced recently that Komboglyze has been approved by the European Commission (EC) in European Union (EU). Komboglyze is a combination of Onglyza (saxagliptin), a DPP-4 inhibitor and metformin, a generic drug for...
8Dec2011 | vitalstocks | 0 comments | Continued(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. —...
7Dec2011 | vitalstocks | 0 comments | Continued(MITI) Micromet Begins New Trial
Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic leukemia (ALL). The trial was advised to be conducted by the US...
6Dec2011 | vitalstocks | 0 comments | Continued(MNTA) Momenta Pharmaceuticals and Novartis AG Sue Watson Pharmaceuticals
Momenta Pharmaceuticals, Inc. (MNTA) and Novartis AG (NVS) filed a lawsuit against Amphastar Pharmaceuticals, Inc. and Watson Pharmaceuticals Inc. (WPI) regarding the generic version of Sanofi-Aventis’ (SNY) Lovenox. The lawsuit was filed in United States District Court for...
24Sep2011 | vitalstocks | 0 comments | Continued(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
23Sep2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca Coverage Initiated at Neutral
We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines...
21Sep2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca’s Brilinta Now in US
AstraZeneca plc (AZN) recently announced the US launch of Brilinta (ticagrelor). The drug was approved by the US Food and Drug Administration (FDA) last month, to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS). Following...
15Sep2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Analyst Maintains Outperform on Shares
We continue to have an Outperform recommendation on Watson Pharmaceuticals, Inc. (WPI), with a target price of $79.00, following the release of second quarter 2011 results. Watson Pharma’s second quarter earnings of $1.01 per share (excluding special items) outpaced the Zacks...
26Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Analyst Reaffirms Shares at Neutral
We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results. Mylan’s second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus...
25Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle
Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA) filed by Mylan with the US Food and Drug Administration (FDA) for the generic version of Endo’s acute migraine...
18Aug2011 | vitalstocks | 0 comments | Continued(MITI) Micromet Loss Less Than Analyst Estimates – Revenues Rise
Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting for the change in fair value of warrants). The loss was, however, narrower...
9Aug2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Company Reports Solid Quarter
Bristol-Myers Squibb Company’s (BMY) second quarter 2011 earnings (excluding special items) of $0.56 per share surpassed the Zacks Consensus Estimate by $0.01and the year-ago earnings by $0.02. Higher revenues boosted earnings in the reported quarter. On a reported basis (including...
3Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Beats Second Quarter Earnings on All Fronts
Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven by increase in generics revenue and improved...
27Jul2011 | vitalstocks | 0 comments | Continued(KCI) Kinetic Concepts Aquired by Apax Partners and Two Canadian Pension Funds
Private equity firm Apax Partners and two Canadian pension funds are set to acquire leading medical technology company Kinetic Concepts (KCI). The deal, including Kinetic’s outstanding debt, is valued at approximately $6.3 billion. As an independent global partnership,...
14Jul2011 | vitalstocks | 0 comments | Continued(MITI) Micromet Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $6.00 per share. We believe Micromet’s lead pipeline candidate, blinatumomab, holds tremendous potential in the treatment of Acute lymphoblastic leukemia (ALL). Blinatumomub is one of the leading...
6Jul2011 | vitalstocks | 0 comments | Continued(PRX) Par Pharmaceutical Restructures Branded Business
Par Pharmaceutical Companies, Inc. (PRX) is in for a strategic assessment as it announced restructuring plans for its branded drugs segment, Strativa Pharmaceuticals. The company will reduce its workforce by about 100 people as a result of the restructuring, which is expected...
5Jul2011 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform
Recently, we upgraded Myriad Genetics (MYGN) to Outperform with a target price of $27.00. Myriad is confident of retaining the momentum recorded over the past few quarters going ahead through product portfolio expansion, targeting the companion diagnostic market and expansion...
1Jul2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Company Presents Data on Two Studies
Recently, Bristol-Myers Squibb Company (BMY) and partner AstraZeneca (AZN) presented encouraging data from two late-stage studies which evaluated their type II diabetes candidate dapagliflozin in conjunction with the extended-release version of metformin (XR). Data from the two...
29Jun2011 | vitalstocks | 0 comments | Continued(LIFE) Life Technologies Ties Up with Pharma Majors
Life Technologies Corporation (LIFE) recently strengthened its newly created Technology Strategy Board grant consortium with the inclusion of the R&D divisions of AstraZeneca (AZN) and Johnson & Johnson (JNJ). The group expects this grant to fund the development of a...
27Jun2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb and Pfizer Report Positive Data on Blood Thinner Apixaban Drug
Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging top line data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner apixaban in patients suffering from an erratic heartbeat. This cardiac rhythm disorder is...
24Jun2011 | vitalstocks | 0 comments | Continued(XRAY) DENTSPLY Grabs Astra Tech for $1.8 Billion
In a bid to bolster its foothold in the global dental market, leading dental products maker DENTSPLY International (XRAY) has agreed to buy Astra Tech, the dental implant division of multinational drug major AstraZeneca PLC (AZN), for $1.8 billion in cash. The Anglo-Swiss pharmaceutical...
23Jun2011 | vitalstocks | 0 comments | Continued(APOG) Company News for June 23, 2011 – Corporate Summary
• Shares of Robbins & Myers, Inc. (NYSE:RBN) jumped 8.77% on strong fiscal third-quarter profits. The energy equipment supplier said strong customer demand and the recent acquisition of oilfield services has helped the company’s increase its profits • ...
23Jun2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Company Gets Another Feather in its Cap
Bristol-Myers Squibb Company’s (BMY) product portfolio was boosted further when the US Food and Drug Administration (FDA) approved its drug Nulojix (belatacept) to prevent the rejection of transplanted kidneys in adults. We remind investors that Bristol-Myers has succeeded...
17Jun2011 | vitalstocks | 0 comments | Continued(MAA) Roche Holdings’ Skin Cancer Drug Impresses
Roche Holdings Ltd. (RHHBY) recently presented encouraging data from a phase III trial (BRIM 3) on BRAF V600 mutation-positive metastatic melanoma candidate, vemurafenib (RG7204, PLX4032), at the annual meeting of the American Society of Clinical Oncology (ASCO). The BRIM 3 study...
12Jun2011 | vitalstocks | 0 comments | Continued(AFFX) Company News for June 03, 2011 – Corporate Summary
• Joy Global Inc. (NASDAQ:JOYG) posted Q2 EPS of $1.52, higher than the Zacks Consensus Estimate of $1.35 per share. Revenue for the quarter grew 19% to $1.06 billion, beating the Zacks Consensus Estimate of $1.038 billion • According to reports, Ford Motor Co...
3Jun2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca Revenues Fall – Outlook Improves
AstraZeneca plc (AZN) reported first-quarter fiscal 2011 core earnings of $2.23 per American Depositary Share (ADS), reflecting an increase of 10% (at constant exchange rates [CER]) from the prior-year quarter. The Zacks Consensus Estimate for the reported quarter was $2.04 per...
3May2011 | vitalstocks | 0 comments | Continued(ABT) Abbott Labs First Quarter 2011 Earnings Preview
Abbott Laboratories (ABT) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing a year-over-year increase of 11.1%. Abbott Labs has surpassed earnings...
18Apr2011 | vitalstocks | 0 comments | Continued